The quarter missed already-low expectations on both earnings and sales. Adjusted diluted EPS was $0.21 versus published consensus of roughly $0.225, while net sales were $1.193 billion versus approximately $1.229 billion expected. That makes this a genuine earnings miss, not merely a weak year-over-year comparison.
| Metric | Q2 2026 | Q2 2025 | Change / expectation |
|---|---|---|---|
| Net sales | $1.193B | $1.243B | -4.0%; vs ~$1.229B consensus |
| Adjusted diluted EPS | $0.21 | $0.30 | -$0.09; vs ~$0.225 consensus |
| Adjusted EBITDA | $111.3M | $137.7M | -19.2% |
| Adjusted EBITDA margin | 9.3% | 11.1% | -180 bps |
| Total volume | — | — | -5.8% |
The core problem was volume, not insufficient pricing. Consolidated pricing/mix rose 1.8%, but volume fell 5.8%; branded retail volume dropped 7.6%, showing that price increases did not offset weaker consumer demand. (Net Sales Bridge) The company said, “Net sales decreased 4.0% to $1.193 billion as favorable price/mix was more than offset by lower volume.”
Profitability deteriorated materially beyond the sales decline. Adjusted EBITDA fell 19.2% and margin compressed 180 basis points as labor, freight, marketing, and lower production volumes pressured costs. (Consolidated Second Quarter Operating Highlights) The filing states, “Selling, distribution, and administrative (SD&A) expenses were 39.7% of net sales, a 160-basis point increase.” 〔0〕 This indicates the miss reflects weaker operating leverage and cost pressure, not just a temporary accounting item.
The bigger negative is the full-year reset. Fiscal 2026 sales guidance fell to $5.070 billion-$5.142 billion from $5.163 billion-$5.267 billion; adjusted EBITDA fell to $453 million-$481 million from $465 million-$495 million; and adjusted EPS fell to $0.75-$0.85 from $0.80-$0.90. (Revised Outlook) The company explicitly said, “Given our first-half performance and the current category environment, we are updating our full-year outlook to reflect a more cautious view for the balance of 2026.” 〔1〕
Net read: a broad miss with lowered expectations ahead. The weaker category environment was partly anticipated, but the scale of the volume decline, margin damage, and guidance cuts shows conditions were worse than the standing expectation. Nature’s Own relaunch and organizational realignment are potential recovery efforts, but the filing says the relaunch “has not yet meaningfully contributed to results,” leaving no near-term offset to the downgrade. 〔2〕
Read the original 8-K on SEC EDGAR ↗